# Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C

> **NCT00088504** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 315 (—)

## Conditions studied

- Hepatitis C
- Hepatitis

## Interventions

- **DRUG:** Merimepodib
- **DRUG:** PEG-Interferon-alpha 2a (Pegasys®)
- **DRUG:** Ribavirin (Copegus®)

## Key facts

- **NCT ID:** NCT00088504
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** 315 (—)
- **Last updated:** 2007-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088504, "Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00088504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*